Akorn Gets Warning Letter from FDA

Akorn Pharma's Decatur, Illinois plant has received a warning letter for GMP violations in the manufacture of  its IC-Green intravenous dye.� Ouch.
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


  • <p>One could say that supply chain security is the most critical issue facing drug manufacturers today—and perhaps facing our healthcare system as well. The supply chain is at the heart of healthcare’s greatest problems—drug counterfeiting and adulteration, shortages of key medicines, and of course escalating medical costs. Without security of supply, none of these challenges can be addressed. <a href="http://www.securityplusdumps.net">security training</a> | <a href="http://www.securityplusguide.com">security test</a> | <a href="http://www.mcsadumps.net">mcsa</a> | <a href="http://www.mcsanotes.com">mcsa certification</a> | <a href="http://www.mcsatests.net">mcsa training</a> | <a href="http://www.1y0-259.com">1y0-259</a> | <a href="http://www.1z0-042.com">1z0-042</a> | <a href="http://www.220-701.us">220-701</a> | </p>


RSS feed for comments on this page | RSS feed for all comments